OrbiMed’s Amneal Pharmaceuticals AMRX Stock Holding History

OrbiMed’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,583,490	Closed	-$3.15M	–	126
2022 Q4	$3.15M	Hold	1,583,490	–	–	0.06%	98
2022 Q3	$3.2K	Buy	+1,583,490	New	+$4.44M	0.06%	113

Other funds holding AMRX

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

OrbiMed's AMRX Position: Q1 2023 in Review

OrbiMed sold out of Amneal Pharmaceuticals (AMRX) in Q1 2023, closing a stake of 1,583,490 shares — an estimated $3.15M sold.

OrbiMed first reported a position in AMRX in Q3 2022 and held it in 2 quarters. The position peaked at $3.15M in Q4 2022. 144 funds tracked by Wall St. Rank hold AMRX as of Q1 2023.

OrbiMed reported no remaining Amneal Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
OrbiMed sold 1,583,490 Amneal Pharmaceuticals shares in Q1 2023, an estimated $3.15M.
OrbiMed first reported a position in Amneal Pharmaceuticals in Q3 2022 and held it in 2 quarters.
OrbiMed's Amneal Pharmaceuticals position peaked at $3.15M in Q4 2022.
144 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2023.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.